Nov 29, 2022 / 09:30PM GMT
Joe Catanzaro - Piper Sandler - Analyst
Well, thanks, everybody, for joining us and sticking around through the end of the day here at Piper Sandler's Annual Healthcare Conference. I'm Joe Catanzaro, I'm from the Piper biotech team. It's my pleasure to welcome the full team from ESSA Pharma here, David Parkinson, their CEO, Peter Virsik their COO, and David Wood, their CFO. Joining us here today.
A lot to run through in the next 25 minutes or so. But maybe first, David, I could just sort of hand to you, give us sort of 30, 60 second overview of what you guys have been up to and what we have to look forward to over the next six to 12 months?
David Parkinson - ESSA Pharma Inc. - President, CEO & Director
Sure, Joe. Thanks for the opportunity by the way. And so, what we are doing at ESSA is approaching a novel way of shutting down male hormone or androgen driven biology. Prostate cancer has been known for 60, 70 years to be, in its early stages in particular, entirely driven by androgen driven biology.
There's a 60-year history of developing
ESSA Pharma Inc at Piper Sandler Healthcare Conference Transcript
Nov 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers